- Home
- OSRH vs TPST Comparison
OSRH vs TPST Comparison
Compare OSRH & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | TPST |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OSRH | TPST |
|---|---|---|
| Price | $0.52 | $2.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.1M | 89.6K |
| Earning Date | 04-22-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $2.17 |
| 52 Week High | $11.30 | $12.48 |
Technical Indicators
Market Signals| Indicator | OSRH | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 38.06 |
| Support Level | $0.49 | $2.17 |
| Resistance Level | $0.58 | $2.50 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 8.84 | 23.47 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.